BRNS
Barinthus Biotherapeutics PLC - ADR

171
Mkt Cap
$46.8M
Volume
9,610.00
52W High
$2.92
52W Low
$0.64
PE Ratio
-0.64
BRNS Fundamentals
Price
$1.12
Prev Close
$1.16
Open
$1.19
50D MA
$1.26
Beta
0.76
Avg. Volume
105,431.22
EPS (Annual)
-$1.55
P/B
0.44
Rev/Employee
$142,621.89
Loading...
Loading...
News
all
press releases
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with...
PR Newswire·13d ago
News Placeholder
More News
News Placeholder
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of...
PR Newswire·20d ago
News Placeholder
Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics
Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.
Stocktwits·1mo ago
News Placeholder
Barclays Remains a Buy on Barinthus Biotherapeutics (BRNS)
Barclays analyst Carter Gould maintained a Buy rating on Barinthus Biotherapeutics (BRNS Research Report) today and set a price target of $3.00...
TipRanks Financial Blog·1y ago
News Placeholder
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives
Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were...
Benzinga·2y ago
News Placeholder
Barinthus Biotherapeutics (NASDAQ:BRNS) PT Lowered to $8.00 at HC Wainwright
Barinthus Biotherapeutics (NASDAQ:BRNS Free Report) had its price objective cut by HC Wainwright from $15.00 to $8.00 in a research report released on Thursday, Benzinga reports. They...
Ticker Report·2y ago
News Placeholder
Barinthus Biotherapeutics Reports Significant Financial Shifts and Clinical Progress in 2023
Despite Revenue Decline, R&D Advances Signal Strong Future PotentialRelated Stocks: BRNS...
GuruFocus·2y ago
News Placeholder
Wall Street Analysts Are Bullish on Top Healthcare Picks
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Context Therapeutics (CNTX Research Report) and Barinthus Biotherapeutics...
TipRanks Financial Blog·2y ago
News Placeholder
Barinthus Biotherapeutics: Q4 Earnings Insights
read more...
Benzinga·2y ago
News Placeholder
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
OXFORD, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31...
Globe Newswire·2y ago

Latest BRNS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.